• CCR7–Notch1 Crosstalk Maintains Stemness in Mammary Tumors

  2026-05-13

  Boyle et al. reveal that the chemokine receptor CCR7 directly interacts with Notch1 signaling to maintain cancer stem-like cell properties in mammary tumors. This mechanistic insight highlights the potential for dual pathway targeting in combating therapy resistance in breast cancer.

• Sulfamonomethoxine: Mechanistic Insights and Ecological Impa

  2026-05-12

  Explore Sulfamonomethoxine’s advanced mechanism as a veterinary antibiotic and its ecological impact. This article uniquely bridges molecular action, environmental fate, and assay design, providing researchers with actionable, evidence-based guidance.

• RHEB Neddylation by UBE2F-SAG Axis Drives mTORC1 in Liver Ca

  2026-05-12

  This study uncovers RHEB as a direct neddylation substrate of the UBE2F-SAG axis, revealing a previously uncharacterized mechanism that enhances mTORC1 activity and exacerbates liver tumorigenesis. These findings highlight new molecular targets for translational research on hepatocellular carcinoma and metabolic liver diseases.

• Novobiocin: Applied Antibacterial and Antiviral Workflows

  2026-05-11

  Novobiocin’s unique dual targeting of DNA gyrase and Hsp90 empowers researchers to tackle antibacterial resistance and emerging viral threats with precision. This guide details optimized experimental workflows, troubleshooting strategies, and practical considerations for leveraging Novobiocin in advanced translational research.

• Sodium Overload Impairs Mitochondria to Drive NECSO Patholog

  2026-05-11

  The referenced study uncovers how sodium influx disrupts mitochondrial energy metabolism and triggers necrosis via the NECSO pathway. This mechanistic insight clarifies the link between sodium overload, mitochondrial dysfunction, and cell death, informing future research on ion-driven pathology and mitochondrial assays.

• Bromodomain Inhibitor, (+)-JQ1: Paradigm Shifts in BET Targe

  2026-05-10

  Explore how Bromodomain Inhibitor, (+)-JQ1 uniquely advances BET bromodomain research in cancer and immunology. Delve into mechanistic breakthroughs, practical assay impact, and emerging applications that distinguish this potent BET bromodomain inhibitor.

• KPT330 Enhances Precision of Cas9 Editing by Regulating mRNA

  2026-05-09

  The referenced study reveals that KPT330, an FDA-approved small molecule, improves the specificity of CRISPR-Cas9 genome and base editing by selectively interfering with the nuclear export of Cas9 mRNA. This work introduces a new class of indirect CRISPR modulators, with important implications for minimizing off-target effects and advancing precision genome engineering in mammalian cells.

• Amyloid β-Peptide (1-42): Microglial Phagocytosis and Ion Ch

  2026-05-08

  Explore how Amyloid β-Peptide (1-42) (Aβ42 peptide) drives microglial phagocytic responses and ion channel modulation in Alzheimer’s disease models. This article offers a deeper mechanistic perspective and practical assay guidance distinct from existing workflow-focused content.

• Nav1.6 Drives Glioblastoma Proliferation via NHE1 and AKT/ER

  2026-05-08

  This study uncovers how voltage-gated sodium channel Nav1.6 promotes glioblastoma cell proliferation and migration by interacting with Na+/H+ Exchanger-1 (NHE1) and activating ERK and AKT survival pathways. Targeting both Nav1.6 and NHE1 offers a promising strategy to inhibit glioblastoma progression and induce apoptosis, providing new avenues for therapeutic intervention.

• Reliable Cell Proliferation and Viability with Cell Counting

  2026-05-07

  This article provides scenario-driven guidance for optimizing cell proliferation, viability, and cytotoxicity assays using Cell Counting Kit-8 (CCK-8), SKU K1018. It addresses laboratory challenges from assay principle to vendor selection, with evidence-based recommendations for maximizing reproducibility and sensitivity in biomedical research workflows.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe Gui

  2026-05-07

  DiI (DiIC18(3)) is a lipophilic fluorescent probe designed for selective plasma membrane labeling in cells and tissues, supporting applications like neuronal tracing and cell migration assays. It should not be used in protocols requiring water solubility or organelle-specific staining, and strict protocol adherence is necessary to avoid loss of signal or non-specific background.

• Nonconventional GLP-1R Antagonist Interplay Mapped by FRET A

  2026-05-06

  This study redefines the selectivity landscape of glucagon and GLP-1 receptor signaling by uncovering unexpected agonist and antagonist interactions at the GLP-1 receptor using high-throughput FRET assays for cAMP. These findings challenge prior assumptions about receptor specificity and inform the design of peptide antagonists for metabolic and type 2 diabetes research.

• Metoprolol in Translational Research: Pharmacodynamics, Anti

  2026-05-06

  Explore how Metoprolol, a selective beta1-adrenoceptor antagonist, advances cardiovascular and cancer biology research by bridging pharmacodynamic action with microenvironmental modulation. This article uniquely examines tissue distribution, anti-inflammatory roles, and assay design, offering practical insights distinct from existing guides.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-05-05

  This study demonstrates that PPARγ activation regulates macrophage polarization, shifting cells from a proinflammatory M1 to an anti-inflammatory M2 phenotype in murine and cell models of inflammatory bowel disease (IBD). These findings clarify the STAT-1/STAT-6 pathway’s role in intestinal inflammation, informing mechanistic approaches in immunometabolic and type 2 diabetes research.

• VX-745: Advancing Translational Research with Dual-Action p3

  2026-05-05

  This article provides translational researchers with a mechanistic and strategic roadmap to leveraging VX-745, a highly selective p38α MAPK inhibitor, for advanced studies in inflammation, cancer, and drug resistance. Integrating recent structural insights and dual-action kinase inhibition, the article delivers actionable protocol guidance and explores how VX-745, available from APExBIO, empowers next-generation research beyond conventional product overviews.

16612 records 1/1108 page Next 12345 下5页 Last page